What Melanotan II is
Melanotan II (MT-II) is a synthetic cyclic heptapeptide with the sequence cyclo[Nle4,D-Phe7]-alpha-MSH(4-10). Victor Hruby's medicinal chemistry group at the University of Arizona designed it as a smaller, more metabolically stable version of alpha-melanocyte-stimulating hormone (alpha-MSH), a 13-amino acid peptide produced by the pituitary gland. The cyclization connects side chains at positions 4 and 10, creating a conformationally constrained ring that binds more readily to the melanocortin receptor binding pocket than the native linear peptide.
Two non-natural amino acid substitutions define MT-II's pharmacology. Norleucine (Nle) replaces methionine at position 4, removing an oxidation-prone residue and improving chemical stability. D-phenylalanine replaces L-phenylalanine at position 7, conferring resistance to enzymatic cleavage by endopeptidases. Together, these modifications extend half-life and increase receptor binding affinity relative to native alpha-MSH.
The same Arizona group also developed a related linear compound, [Nle4,D-Phe7]-alpha-MSH, called Melanotan-I (MT-I). MT-I is the full 13-amino acid linear peptide; MT-II is the shorter 7-amino acid cyclic version. Both came out of the same research program. Hadley, Hruby, Dorr, Levine, and colleagues published a review of both compounds' development history, structural chemistry, and early trial results in Pharmaceutical Biotechnology (Hadley et al., Pharm Biotechnol 1998;11:575-95, PMID 9760697).
Melanocortin receptor pharmacology
Alpha-MSH acts through five G protein-coupled receptor subtypes (MC1R through MC5R). All five signal primarily through Gs protein coupling, which activates adenylyl cyclase and raises intracellular cyclic AMP. MT-II is a non-selective agonist across all five subtypes, and its range of observed biological effects maps directly onto which receptors are activated and in which tissues.
MC1R sits on epidermal melanocytes and drives melanogenesis. Agonism here triggers a switch from reddish-yellow phaeomelanin toward brown-black eumelanin, producing the tanning effect. MC4R is the primary mediator of the sexual arousal and appetite-suppressing effects. It is expressed in the paraventricular nucleus and medial preoptic area of the hypothalamus, regions involved in sexual function, food intake, and energy homeostasis. Activation of hypothalamic MC4R increases oxytocin and dopamine release through pathways that control arousal, which is the proximate mechanism for the erectogenic effects seen in trials. MC3R is also expressed in the hypothalamus and limbic structures; its specific contribution to MT-II's in-human effects has not been fully characterized. MC5R is found in exocrine glands and may contribute to secretory side effects at higher doses.
MT-II's non-selective receptor engagement means it simultaneously activates pigmentation, sexual arousal, appetite, and nausea pathways. This is why the compound produced effects across multiple physiological systems in clinical testing, and why separating the intended effect from concurrent activation of other receptors proved difficult without structural modifications.
The Arizona development program and tanning studies
The tanning program began with MT-I. Levine and colleagues at the University of Arizona Health Sciences Center ran the first randomized, double-blind, placebo-controlled human trial using the linear NDP-alpha-MSH analogue. Their 1991 JAMA paper (Levine et al., JAMA 1991;266:2730-6, n=28, PMID 1658407) enrolled 28 healthy white men with either poor tanning (skin types I and II) or good tanning (skin types III and IV) history. Each subject received 10 subcutaneous injections over 12 days. Treated subjects in both groups showed significant skin darkening compared to baseline (p less than 0.001 for type I/II; p substantially less than 0.001 for type III/IV), while no darkening occurred in placebo subjects.
MT-II was developed as the next generation. Its cyclic structure provided greater potency at melanocortin receptors than the linear MT-I, which was the explicit design goal. The Arizona group's rationale was photoprotection: stimulating eumelanin synthesis without UV exposure could theoretically reduce photodamage and skin cancer risk in fair-skinned individuals who tan poorly. A formal tanning efficacy program for MT-II itself did not advance to large controlled registration trials before the program's focus shifted to the erectile dysfunction finding.
Researchers working with either MT-I or MT-II during tanning studies reported an unexpected observation: male volunteers developed spontaneous erections and increased libido during dosing. This observation shifted the research priority toward MC4R's role in sexual function and drove the next phase of clinical work.
Erectile dysfunction trial data
Wessells and colleagues at the University of Arizona ran a double-blind, placebo-controlled crossover trial in 10 men with psychogenic erectile dysfunction. Each subject received subcutaneous MT-II at 0.025 mg/kg or vehicle placebo. Erectile activity was monitored continuously by RigiScan. Eight of 10 men treated with MT-II developed clinically apparent erections. Mean duration of tip rigidity above 80% was 38.0 minutes with MT-II versus 3.0 minutes with placebo (p=0.0045). Mean time from injection to the first measurable erection was approximately 2 hours, with a range of 15 to 270 minutes (Wessells et al., J Urol 1998;160:389-93, PMID 9679884).
A follow-up study examined MT-II in men with organic erectile dysfunction rather than psychogenic. Using the same double-blind, placebo-controlled crossover design with 10 subjects and the same 0.025 mg/kg subcutaneous dose, investigators reported erections and increased sexual desire in treated subjects compared to placebo (Urology 2000; PMID 11018622).
Neither trial scaled to a Phase 3 program for MT-II. The findings established proof of concept for central MC4R-mediated erection initiation, but the compound's side effect profile at effective doses, and the absence of a pharmaceutical sponsor to fund registration-grade trials, meant the program remained at Phase 2.
Researchers calculating weight-based doses for in-model studies can use the dosing calculator to convert mg/kg protocols to solution volumes based on reconstitution concentration.
Side effects observed in clinical studies
Nausea was the most common adverse effect reported across MT-II trials and occurred after single subcutaneous doses at 0.025 mg/kg. The mechanism is consistent with MC4R activation in the area postrema and nucleus tractus solitarius, brainstem regions that regulate nausea and emesis. In the Wessells 1998 study, nausea was transient and did not require treatment in any subject, but it was a consistent finding across participants.
Other reported effects included facial flushing, yawning, stretching, spontaneous erections in male participants (including those not enrolled in the ED trials), and decreased appetite. The appetite suppression is also MC4R-mediated. Facial flushing likely involves MC5R in peripheral vasculature and sweat glands.
At doses above those used in the published trials, blood pressure increases were documented. These cardiovascular signals became a design constraint for subsequent melanocortin drug development. When Palatin Technologies later reformulated the pharmacophore as an intranasal spray for erectile dysfunction, early Phase 2 data showed dose-dependent blood pressure increases that drove a reformulation to subcutaneous injection and a pivot in the target indication.
Regulatory status and the bremelanotide lineage
Melanotan II itself was never submitted to the FDA or EMA for approval. The University of Arizona program was academic and investigational; no pharmaceutical sponsor advanced MT-II through a registration-grade Phase 3 program for any indication.
The MC4R erectogenic mechanism established in MT-II trials did directly inform commercial drug development. Palatin Technologies identified the same pharmacophore and developed bremelanotide (PT-141), a modified melanocortin receptor agonist. Bremelanotide entered clinical development as an intranasal spray for erectile dysfunction in men. Early Phase 2 signals showing blood pressure increases led to reformulation as a subcutaneous injection and a pivot to hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA approved bremelanotide as Vyleesi on June 21, 2019, the first melanocortin receptor agonist approved for HSDD.
MT-II itself remains outside the regulatory approval framework in all jurisdictions. It is not classified as a controlled substance in most countries but is also not approved for any human therapeutic indication. Research use must remain within applicable regulations governing unapproved investigational compounds. The full clinical trial history for bremelanotide (PT-141) is covered separately.
The full compound catalog, including other melanocortin-related research peptides, is at /#compounds.